SAN DIEGO, July 13, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024, all dates inclusive (the “Class Period”), have until July 22, 2024 to seek appointment as lead plaintiff in the Biogen class action lawsuit. Captioned Gray v. Biogen Inc., No. 24-cv-01444 (D. Colo.), the Biogen class action lawsuit charges Biogen as well as certain of Biogen’s top current and former execu ...

NEW YORK, July 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB).Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=90352&from=4 CLASS PERIOD: February 3, 2022 to February 13, 2 ...

NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biogen investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 13, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/biogen-lawsuit-submission-form? ...

NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=89664&from=3 CLASS PERIOD: February 3, 2022 to Februar ...

RADNOR, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc. (“Biogen”) (NASDAQ: BIIB). The action charges Biogen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of Biogen’s ...

SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024. Biogen is a global biopharmaceutical company that discovers, develops, and delivers therapies for people living with serious and complex diseases worldwide. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a ...

LOS ANGELES, July 2, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period"), are e ...

CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). “We are very excited about the addition of felzartamab into our pipeline, further strengthening our presence in immunology with a promising late-stage therapeutic candidate being studied in multiple indications,” said ...

文章核心观点 - 生物医药公司Biogen完成收购了专注于针对严重免疫介导性疾病的靶向疗法的生物技术公司Human Immunology Biosciences (HI-Bio) [1][2] - 收购后,Biogen将与HI-Bio团队合作,推进其主要候选药物felzartamab的III期临床试验,用于治疗抗体介导性排斥反应(AMR)、IgA肾病(IgAN)和原发性膜性肾病(PMN)等罕见疾病 [2][3] - felzartamab是一种针对CD38蛋白的人源化单克隆抗体,可选择性耗竭CD38+浆细胞,在多发性骨髓瘤等疾病中显示出临床疗效 [3][4] 公司概况 - Biogen是一家领先的生物技术公司,专注于创新科学,为患者提供新药物,为股东和社区创造价值 [6][7] - Biogen采取大胆的风险承担策略,同时注重投资回报,以实现长期增长 [7] 行业概况 - AMR是肾移植失败的主要原因之一,约12%的肾移植患者受到慢性AMR的影响,目前治疗方案有限 [5] - PMN是一种罕见的免疫介导性肾脏疾病,目前尚无获批的治疗方案 [5] - IgAN是全球最常见的原发性肾小球肾炎,约40%的患者会在诊断后20年内进展为终末期肾病 [6]

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=88052&from=3 CLASS PERIOD: February 3, 2022 to Februar ...